Splice switching oligonucleotides as potential therapeutics

Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition

Volumn , Issue , 2007, Pages 89-114

  Sazani, Peter ^a   Graziewicz, Maria A ^a   Kole, Ryszard ^b  

^a Ercole Biotech Inc   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057657830     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (217)

1. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD, Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays, Science, 302, 2141-2144, 2003.
2. Modrek B, Lee C, A genomic view of alternative splicing, Nat Genet, 30, 13-19, 2002.
3. Graveley BR, Alternative splicing: increasing diversity in the proteomic world, Trends Genet, 17, 100-107, 2001.
4. Pascual M, Vicente M, Monferrer L, Artero R, The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing, Differentiation, 74, 65-80, 2006.
5. Schwerk C, Schulze-Osthoff K, Regulation of apoptosis by alternative pre-mRNA splicing, Mol Cell, 19, 1-13, 2005.
6. Pan YX, Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters, DNA Cell Biol, 24, 736-750, 2005.
7. Kalnina Z, Zayakin P, Silina K, Line A, Alterations of pre-mRNA splicing in cancer, Genes Chromosomes Cancer, 42, 342-357, 2005.
8. Matlin AJ, Clark F, Smith CW, Understanding alternative splicing: towards a cellular code, Nat Rev Mol Cell Biol, 6, 386-398, 2005.
9. Caceres JF, Kornblihtt AR, Alternative splicing: multiple control mechanisms and involvement in human disease, Trends Genet, 18, 186-193, 2002.
10. Faustino NA, Cooper TA, Pre-mRNA splicing and human disease, Genes Dev, 17, 419-437, 2003.
11. Pagani F, Baralle FE, Genomic variants in exons and introns: identifying the splicing spoilers, Nat Rev Genet, 5, 389-396, 2004.
12. Crooke S, Antisense Drug Technology, Marcel Dekker, New York, 2001.
13. Cartegni L, Chew SL, Krainer AR, Listening to silence and understanding nonsense: exonic mutations that affect splicing, Nat Rev Genet, 3, 285-298, 2002.
14. Spellman R, Rideau A, Matlin A, Gooding C, Robinson F, McGlincy N, Grellscheid SN, Southby J, Wollerton M, Smith CW, Regulation of alternative splicing by PTB and associated factors, Biochem Soc Trans, 33, 457-460, 2005.
15. Staley JP, Guthrie C, Mechanical devices of the spliceosome: motors, clocks, springs, and things, Cell, 92, 315-326, 1998.
16. Burge C, Tuschl T, Sharp P, Splicing of precursors to mRNAs by the spliceosomes, In: The RNA World, 2, Gesteland R, Cech T, Atkins J, eds., CSHL Press, Cold Spring Harbor, NY, 1999, pp. 525-560.
17. Penalva LO, Ruiz MF, Ortega A, Granadino B, Vicente L, Segarra C, Valcarcel J, Sanchez L, The Drosophila fl(2)d gene, required for female-specific splicing of Sxl and tra pre-mRNAs, encodes a novel nuclear protein with an HQ-rich domain, Genetics, 155, 129-139, 2000.
18. Krecic AM, Swanson MS, hnRNP complexes: composition, structure, and function, Curr Opin Cell Biol, 11, 363-371, 1999.
19. Dreyfuss G, Kim VN, Kataoka N, Messenger-RNA-binding proteins and the messages they carry, Nat Rev Mol Cell Biol, 3, 195-205, 2002.
20. Hoffman BE, Grabowski PJ, U1 snRNP targets an essential splicing factor, U2AF65, to the 3′ splice site by a network of interactions spanning the exon, Genes Dev, 6, 2554-2568, 1992.
21. Zahler AM, Lane WS, Stolk JA, Roth MB, SR proteins: a conserved family of pre-mRNA splicing factors, Genes Dev, 6, 837-847, 1992.
22. Zahler AM, Neugebauer KM, Lane WS, Roth MB, Distinct functions of SR proteins in alternative premRNA splicing, Science, 260, 219-222, 1993.
23. Fu XD, The superfamily of arginine/serine-rich splicing factors, RNA, 1, 663-680, 1995.
24. Wang Z, Hoffmann HM, Grabowski PJ, Intrinsic U2AF binding is modulated by exon enhancer signals in parallel with changes in splicing activity, RNA, 1, 21-35, 1995.
25. Manley JL, Tacke R, SR proteins and splicing control, Genes Dev, 10, 1569-1579, 1996.
26. Blencowe BJ, Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases, Trends Biochem Sci, 25, 106-110, 2000.
27. Black DL, Mechanisms of alternative pre-messenger RNA splicing, Annu Rev Biochem, 72, 291-336, 2003.
28. Lynch KW, Maniatis T, Assembly of specific SR protein complexes on distinct regulatory elements of the Drosophila doublesex splicing enhancer, Genes Dev, 10, 2089-2101, 1996.
29. Shen H, Kan JL, Green MR, Arginine-serine-rich domains bound at splicing enhancers contact the branchpoint to promote prespliceosome assembly, Mol Cell, 13, 367-376, 2004.
30. Shen H, Green MR, A pathway of sequential arginine-serine-rich domain-splicing signal interactions during mammalian spliceosome assembly, Mol Cell, 16, 363-373, 2004.
31. Krainer A, Eukaryotic mRNA Processing, Oxford University Press, Oxford, 1997.
32. Yu YT, Scharl, EC, Smith, CM, Steitz, JA, The Growing World of Small Nuclear Ribonucleoproteins, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY, 1999.
33. Moore MJ, Query, CC, Sharp, PA, Splicing of Precursors to mRNA by the Splicesomes, Cold Spring Harbor Laboratory Press, Cold Spring Harbour, NY, 1993.
34. Lynch KW, Maniatis T, Synergistic interactions between two distinct elements of a regulated splicing enhancer, Genes Dev, 9, 284-293, 1995.
35. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR, ESEfinder: a web resource to identify exonic splicing enhancers, Nucl Acids Res, 31, 3568-3571, 2003.
36. Del Gatto F, Gesnel MC, Breathnach R, The exon sequence TAGG can inhibit splicing, Nucl Acids Res, 24, 2017-2021, 1996.
37. Wang Z, Xiao X, Van Nostrand E, Burge CB, General and specific functions of exonic splicing silencers in splicing control, Mol Cell, 23, 61-70, 2006.
38. Wang Z, Rolish ME, Yeo G, Tung V, Mawson M, Burge CB, Systematic identification and analysis of exonic splicing silencers, Cell, 119, 831-845, 2004.
39. McCarthy EM, Phillips JA, 3rd, Characterization of an intron splice enhancer that regulates alternative splicing of human GH pre-mRNA, Hum Mol Genet, 7, 1491-1496, 1998.
40. Sirand-Pugnet P, Durosay P, Brody E, Marie J, An intronic (A/U)GGG repeat enhances the splicing of an alternative intron of the chicken beta-tropomyosin pre-mRNA, Nucl Acids Res, 23, 3501-3507, 1995.
41. McCullough AJ, Berget SM, G triplets located throughout a class of small vertebrate introns enforce intron borders and regulate splice site selection, Mol Cell Biol, 17, 4562-4571, 1997.
42. Carstens RP, Wagner EJ, Garcia-Blanco MA, An intronic splicing silencer causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through involvement of polypyrimidine tract binding protein, Mol Cell Biol, 20, 7388-7400, 2000.
43. Garcia-Blanco MA, Baraniak AP, Lasda EL, Alternative splicing in disease and therapy, Nat Biotechnol, 22, 535-546, 2004.
44. Dominski Z, Kole R, Cooperation of pre-mRNA sequence elements in splice site selection, Mol Cell Biol, 12, 2108-2114, 1992.
45. Krawczak M, Reiss J, Cooper DN, The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences, Hum Genet, 90, 41-54, 1992.
46. Dominski Z, Kole R, Selection of splice sites in pre-mRNAs with short internal exons, Mol Cell Biol, 11, 6075-6083, 1991.
47. Dominski Z, Kole R, Identification and characterization by antisense oligonucleotides of exon and intron sequences required for splicing, Mol Cell Biol, 14, 7445-7454, 1994.
48. Dominski Z, Kole R, Identification of exon sequences involved in splice site selection, J Biol Chem, 269, 23590-23596, 1994.
49. Dominski Z, Kole R, Effects of exon sequences on splicing of model pre-mRNA substrates in vitro, Acta Biochim Pol, 43, 161-173, 1996.
50. Herbert A, Rich A, RNA processing and the evolution of eukaryotes, Nat Genet, 21, 265-269, 1999.
51. Lopez AJ, Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation, Annu Rev Genet, 32, 279-305, 1998.
52. Wang Y, Selvakumar M, Helfman D, Alternative pre-mRNA splicing, In: Eukaryotic mRNA Processing, Krainer A, ed., Oxford University Press, New York, 1997, pp. 242-278.
53. Caceres JF, Misteli T, Screaton GR, Spector DL, Krainer AR, Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity, J Cell Biol, 138, 225-238, 1997.
54. Caceres JF, Stamm S, Helfman DM, Krainer AR, Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors, Science, 265, 1706-1709, 1994.
55. Roberts GC, Smith CW, Alternative splicing: combinatorial output from the genome, Curr Opin Chem Biol, 6, 375-383, 2002.
56. Smith CW, Valcarcel J, Alternative pre-mRNA splicing: the logic of combinatorial control, Trends Biochem Sci, 25, 381-388, 2000.
57. Gemignani F, Sazani P, Morcos P, Kole R, Temperature-dependent splicing of beta-globin pre-mRNA, Nucl Acids Res, 30, 4592-4598, 2002.
58. Garcia-Blanco MA, Making antisense of splicing, Curr Opin Mol Ther, 7, 476-482, 2005.
59. Bonizzoni P, Rizzi R, Pesole G, Computational methods for alternative splicing prediction, Brief Funct Genomic Proteomic, 5, 46-51, 2006.
60. Castrignano T, Rizzi R, Talamo IG, De Meo PD, Anselmo A, Bonizzoni P, Pesole G, ASPIC: a web resource for alternative splicing prediction and transcript isoforms characterization, Nucl Acids Res, 34, W440-W443, 2006.
61. Foissac S, Schiex T, Integrating alternative splicing detection into gene prediction, BMC Bioinf, 6, 25, 2005.
62. Kim N, Shin S, Lee S, ASmodeler: gene modeling of alternative splicing from genomic alignment of mRNA, EST and protein sequences, Nucl Acids Res, 32, W181-W186, 2004.
63. Dominski Z, Kole R, Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides, Proc Natl Acad Sci USA, 90, 8673-8677, 1993.
64. Vester B, Wengel J, LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA, Biochemistry, 43, 13233-13241, 2004.
65. Mercatante D, Sazani P, Kole R, Modification of alternatice splicing pathways as a potential chemotherapy for cancer and other diseases, Curr. Cancer Drug Targets, 1, 211-230, 2001.
66. Schwartz E, Benz, EJ, The thalassemia syndrome, In: Hematology, Basic Principles and Practice, Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, and Silberstein LE, eds., Churchill Livingstone, London, Edinburgh, 1995, pp. 586-610.
67. Huisman TH, Frequencies of common beta-thalassemia alleles among different populations: variability in clinical severity, Br J Haematol, 75, 454-457, 1990.
68. Lacerra G, Sierakowska H, Carestia C, Fucharoen S, Summerton J, Weller D, Kole R, Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients, Proc Natl Acad Sci USA, 97, 9591-9596, 2000.
69. Suwanmanee T, Sierakowska H, Fucharoen S, Kole R, Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder, Mol Ther, 6, 718-726, 2002.
70. Suwanmanee T, Sierakowska H, Lacerra G, Svasti S, Kirby S, Walsh C, Fucharoen S, Kole R, Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides, Mol Pharmacol, 62, 545-553, 2002.
71. Kole R, Williams T, Cohen L, RNA modulation, repair and remodeling by splice switching oligonucleotides, Acta Biochim Pol, 51, 373-378, 2004.
72. Kole R, Vacek M, Williams T, Modification of alternative splicing by antisense therapeutics, Oligonucleotides, 14, 65-74, 2004.
73. Vacek M, Sazani P, Kole R, Antisense-mediated redirection of mRNA splicing, Cell Mol Life Sci, 60, 825-833, 2003.
74. Sazani P, Kole R, Modulation of alternative splicing by antisense oligonucleotides, Prog Mol Subcell Biol, 31, 217-239, 2003.
75. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, Muller CR, Lindlof M, Kaariainen H et al., The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion, Am J Hum Genet, 45, 498-506, 1989.
76. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G, Modification of splicing in the dystrophin gene in cultured mdx muscle cells by antisense oligoribonucleotides, Hum Mol Genet, 7, 1083-1090, 1998.
77. Wilton SD, Lloyd F, Carville K, Fletcher S, Honeyman K, Agrawal S, Kole R, Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides, Neuromuscular Disord, 9, 330-338, 1999.
78. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, Morgan JE, Partridge TA, Wilton SD, Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse, Proc Natl Acad Sci USA, 98, 42-47, 2001.
79. Dickson G, Hill V, Graham I, Screening for antisense modulation of dystrophin pre-mRNA splicing, Neuromuscular Disord, 12, S67, 2002.
80. Mann CJ, Honeyman K, McClorey G, Fletcher S, Wilton SD, Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy, J Gene Med, 4, 644-654, 2002.
81. McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD, Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD, Gene Ther, 13, 1373-1381, 2006.
82. Wells KE, Fletcher S, Mann CJ, Wilton SD, Wells DJ, Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle, FEBS Lett, 552, 145-149, 2003.
83. Gebski BL, Mann CJ, Fletcher S, Wilton SD, Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle, Hum Mol Genet, 12, 1801-1811, 2003.
84. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, Fletcher S, Partridge TA, Wilton SD, Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse, Nat Med, 9, 1009-1014, 2003.
85. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G, Partridge T, Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles, Proc Natl Acad Sci USA, 102, 198-203, 2005.
86. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, Partridge TA, Lu QL, Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology, Nat Med, 12, 175-177, 2006.
87. Takeshima Y, Wada H, Yagi M, Ishikawa Y, Minami R, Nakamura H, Matsuo M, Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient, Brain Dev, 23, 788-790, 2001.
88. van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT, van Ommen GJ, Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells, Hum Mol Genet, 10, 1547-1554, 2001.
89. Aartsma-Rus A, Bremmer-Bout M, Janson A, den Dunnen J, van Ommen G, van Deutekom J, Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy, Neuromuscular Disord, 12, S71, 2002.
90. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F, van Ommen GJ, van Deutekom JC, Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients, Hum Mol Genet, 12, 907-914, 2003.
91. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, van Deutekom JC, Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense, Am J Hum Genet, 74, 83-92, 2004.
92. Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC, Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells, Gene Ther, 11, 1391-1398, 2004.
93. Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC, Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons, Mol Ther, 14, 401-407, 2006.
94. Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, Kaman WE, Janson AA, Vossen RH, van Ommen GJ, den Dunnen JT, van Deutekom JC, Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides, Mol Ther, 10, 232-240, 2004.
95. Takeshima Y, Yagi M, Wada H, Ishibashi K, Nishiyama A, Kakumoto M, Sakaeda T, Saura R, Okumura K, Matsuo M, Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy, Pediatr Res, 59, 690-694, 2006.
96. Takeshima Y, Yagi M, Wada H, Matsuo M, Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle, Brain Dev, 27, 488-493, 2005.
97. Welsh MJ, Tsui, L-C, Boat, TF, Beaudet, LA, Cystic Fibrosis, McGraw-Hill, New York, 1995.
98. Liu X, Jiang Q, Mansfield SG, Puttaraju M, Zhang Y, Zhou W, Cohn JA, Garcia-Blanco MA, Mitchell LG, Engelhardt JF, Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing, Nat Biotechnol, 20, 47-52, 2002.
99. Liu X, Luo M, Zhang LN, Yan Z, Zak R, Ding W, Mansfield SG, Mitchell LG, Engelhardt JF, Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells, Hum Gene Ther, 16, 1116-1123, 2005.
100. Abeliovich D, Lavon IP, Lerer I, Cohen T, Springer C, Avital A, Cutting GR, Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population, Am J Hum Genet, 51, 951-956, 1992.
101. Friedman KJ, Kole J, Cohn JA, Knowles MR, Silverman LM, Kole R, Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides, J Biol Chem, 274, 36193-36199, 1999.
102. Nissim-Rafinia M, Aviram M, Randell SH, Shushi L, Ozeri E, Chiba-Falek O, Eidelman O, Pollard HB, Yankaskas JR, Kerem B, Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation, EMBO Rep, 5, 1071-1077, 2004.
103. Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E, Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum:implications for Alzheimer’s disease, J Cell Biol, 143, 777-794, 1998.
104. Utton MA, Connell J, Asuni AA, van Slegtenhorst M, Hutton M, de Silva R, Lees AJ, Miller CC, Anderton BH, The slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants in cultured neurons, J Neurosci, 22, 6394-6400, 2002.
105. Andreadis A, Brown WM, Kosik KS, Structure and novel exons of the human tau gene, Biochemistry, 31, 10626-10633, 1992.
106. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA, Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease, Neuron, 3, 519-526, 1989.
107. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA, Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain, EMBO J, 8, 393-399, 1989.
108. Kar A, Kuo D, He R, Zhou J, Wu JY, Tau alternative splicing and frontotemporal dementia, Alzheimer’s Dis Assoc Disord, 19, Suppl 1, S29-S36, 2005.
109. Kalbfuss B, Mabon SA, Misteli T, Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17, J Biol Chem, 276, 42986-42993, 2001.
110. Hoger TH, Zatloukal K, Waizenegger I, Krohne G, Characterization of a second highly conserved B-type lamin present in cells previously thought to contain only a single B-type lamin, Chromosoma, 99, 379-390, 1990.
111. Furukawa K, Hotta Y, cDNA cloning of a germ cell specific lamin B3 from mouse spermatocytes and analysis of its function by ectopic expression in somatic cells, EMBO J, 12, 97-106, 1993.
112. Broers JL, Raymond Y, Rot MK, Kuijpers H, Wagenaar SS, Ramaekers FC, Nuclear A-type lamins are differentially expressed in human lung cancer subtypes, Am J Pathol, 143, 211-220, 1993.
113. Fisher DZ, Chaudhary N, Blobel G, cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins, Proc Natl Acad Sci USA, 83, 6450-6454, 1986.
114. Gerace L, Burke B, Functional organization of the nuclear envelope, Annu Rev Cell Biol, 4, 335-374, 1988.
115. Krohne G, Benavente R, The nuclear lamins. A multigene family of proteins in evolution and differentiation, Exp Cell Res, 162, 1-10, 1986.
116. Lin F, Worman HJ, Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C, J Biol Chem, 268, 16321-16326, 1993.
117. McKeon FD, Kirschner MW, Caput D, Homologies in both primary and secondary structure between nuclear envelope and intermediate filament proteins, Nature, 319, 463-468, 1986.
118. Machiels BM, Zorenc AH, Endert JM, Kuijpers HJ, van Eys GJ, Ramaekers FC, Broers JL, An alternative splicing product of the lamin A/C gene lacks exon 10, J Biol Chem, 271, 9249-9253, 1996.
119. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS, Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome, Nature, 423, 293-298, 2003.
120. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, Levy N, Lamin: a truncation in Hutchinson-Gilford progeria, Science, 300, 2055, 2003.
121. Csoka AB, Cao H, Sammak PJ, Constantinescu D, Schatten GP, Hegele RA, Novel lamin A/C gene (LMNA) mutations in atypical progeroid syndromes, J Med Genet, 41, 304-308, 2004.
122. Scaffidi P, Misteli T, Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome, Nat Med, 11, 440-445, 2005.
123. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M et al., Identification and characterization of a spinal muscular atrophy-determining gene, Cell, 80, 155-165, 1995.
124. Lorson CL, Hahnen E, Androphy EJ, Wirth B, A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy, Proc Natl Acad Sci USA, 96, 6307-6311, 1999.
125. Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH, McPherson JD, A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2, Hum Mol Genet, 8, 1177-1183, 1999.
126. Cartegni L, Hastings ML, Calarco JA, de Stanchina E, Krainer AR, Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2, Am J Hum Genet, 78, 63-77, 2006.
127. Monani UR, Coovert DD, Burghes AH, Animal models of spinal muscular atrophy, Hum Mol Genet, 9, 2451-2457, 2000.
128. Wirth B, Brichta L, Schrank B, Lochmuller H, Blick S, Baasner A, Heller R, Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number, Hum Genet, 119, 422-428, 2006.
129. Brichta L, Holker I, Haug K, Klockgether T, Wirth B, In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate, Ann Neurol, 59, 970-975, 2006.
130. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H, Treatment of spinal muscular atrophy by sodium butyrate, Proc Natl Acad Sci USA, 98, 9808-9813, 2001.
131. Lim SR, Hertel KJ, Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing, J Biol Chem, 276, 45476-45483, 2001.
132. Miyajima H, Miyaso H, Okumura M, Kurisu J, Imaizumi K, Identification of a cis-acting element for the regulation of SMN exon 7 splicing, J Biol Chem, 277, 23271-23277, 2002.
133. Miyaso H, Okumura M, Kondo S, Higashide S, Miyajima H, Imaizumi K, An intronic splicing enhancer element in survival motor neuron (SMN) pre-mRNA, J Biol Chem, 278, 15825-15831, 2003.
134. Singh NK, Singh NN, Androphy EJ, Singh RN, Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron, Mol Cell Biol, 26, 1333-1346, 2006.
135. Vetrini F, Tammaro R, Bondanza S, Surace EM, Auricchio A, De Luca M, Ballabio A, Marigo V, Aberrant splicing in the ocular albinism type 1 gene (OA1/GPR143) is corrected in vitro by morpholino antisense oligonucleotides, Hum Mutat, 27, 420-426, 2006.
136. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB, bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death, Cell, 74, 597-608, 1993.
137. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC, Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers, Am J Pathol, 148, 1567-1576, 1996.
138. Xerri L, Hassoun J, Devilard E, Birnbaum D, Birg F, BCL-X and the apoptotic machinery of lymphoma cells, Leukemia Lymphoma, 28, 451-458, 1998.
139. Taylor JK, Zhang QQ, Wyatt JR, Dean NM, Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides, Nat Biotechnol, 17, 1097-1100, 1999.
140. Taylor MF, Paulauskis JD, Weller DD, Kobzik L, In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-alpha mRNA, J Biol Chem, 271, 17445-17452, 1996.
141. Xu L, Ferry AE, Monteiro C, Pace BS, Beta globin gene inhibition by antisense RNA transcripts, Gene Ther, 7, 438-444, 2000.
142. Nita ME, Ono-Nita SK, Tsuno N, Tominaga O, Takenoue T, Sunami E, Kitayama J, Nakamura Y, Nagawa H, Bcl-X(L) antisense sensitizes human colon cancer cell line to 5-fluorouracil, Jpn J Cancer Res, 91, 825-832, 2000.
143. Heere-Ress E, Thallinger C, Lucas T, Schlagbauer-Wadl H, Wacheck V, Monia BP, Wolff K, Pehamberger H, Jansen B, Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy, Int J Cancer, 99, 29-34, 2002.
144. Wacheck V, Losert D, Gunsberg P, Vornlocher HP, Hadwiger P, Geick A, Pehamberger H, Muller M, Jansen B, Small interfering RNA targeting bcl-2 sensitizes malignant melanoma, Oligonucleotides, 13, 393-400, 2003.
145. Mercatante DR, Mohler JL, Kole R, Cellular response to an antisense-mediated shift of Bcl-x premRNA splicing and antineoplastic agents, J Biol Chem, 14, 14, 2002.
146. Mercatante DR, Kole R, Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression, Biochim Biophys Acta, 1587, 126-132, 2002.
147. Yamamoto T, Nishioka K, Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy, Skin Pharmacol Appl Skin Physiol, 16, 50-58, 2003.
148. Takahashi H, Manabe A, Ishida-Yamamoto A, Hashimoto Y, Iizuka H, Aberrant expression of apoptosis-related molecules in psoriatic epidermis, J Dermatol Sci, 28, 187-197, 2002.
149. Kocak M, Bozdogan O, Erkek E, Atasoy P, Birol A, Examination of Bcl-2, Bcl-X and bax protein expression in psoriasis, Int J Dermatol, 42, 789-793, 2003.
150. Williams T, Kole R, Analysis of prostate-specific membrane antigen splice variants in LNCap cells, Oligonucleotides, 16, 186-195, 2006.
151. Lupold SE, Hicke BJ, Lin Y, Coffey DS, Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen, Cancer Res, 62, 4029-4033, 2002.
152. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, Bander NH, Rajasekaran AK, A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen, Mol Biol Cell, 14, 4835-4845, 2003.
153. Slater RM, Mannens MM, Cytogenetics and molecular genetics of Wilms’ tumor of childhood, Cancer Genet Cytogenet, 61, 111-121, 1992.
154. Saglio G, Carturan S, Grillo S, Capella S, Arruga F, Defilippi I, Rosso V, Rauco M, Marina Liberati A, Cilloni D, WT1 overexpression: a clinically useful marker in acute and chronic myeloid leukemias, Hematology, 10, Suppl 1, 76-78, 2005.
155. Silberstein GB, Van Horn K, Strickland P, Roberts CT, Jr., Daniel CW, Altered expression of the WT1 Wilms’ tumor suppressor gene in human breast cancer, Proc Natl Acad Sci USA, 94, 8132-8137, 1997.
156. Lee SB, Haber DA, Wilms’ tumor and the WT1 gene, Exp Cell Res, 264, 74-99, 2001.
157. Bor YC, Swartz J, Morrison A, Rekosh D, Ladomery M, Hammarskjold ML, The Wilms’ tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron, Genes Dev, 20, 1597-1608, 2006.
158. Renshaw J, King-Underwood L, Pritchard-Jones K, Differential splicing of exon 5 of the Wilms’ tumour (WTI) gene, Genes Chromosomes Cancer, 19, 256-266, 1997.
159. Renshaw J, Orr RM, Walton MI, Te Poele R, Williams RD, Wancewicz EV, Monia BP, Workman P, Pritchard-Jones K, Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival, Mol Cancer Ther, 3, 1467-1484, 2004.
160. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, Anderson DM, Gimpel SD, Davis-Smith T, Maliszewski CR et al., Molecular and biological characterization of a murine ligand for CD40, Nature, 357, 80-82, 1992.
161. Siwkowski AM, Malik L, Esau CC, Maier MA, Wancewicz EV, Albertshofer K, Monia BP, Bennett CF, Eldrup AB, Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing, Nucl Acids Res, 32, 2695-2706, 2004.
162. Vickers TA, Zhang H, Graham MJ, Lemonidis KM, Zhao C, Dean NM, Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2′-Omethoxyethyl-modified oligonucleotide, J Immunol, 176, 3652-3661, 2006.
163. Burns K, Martinon F, Esslinger C, Pahl H, Schneider P, Bodmer JL, Di Marco F, French L, Tschopp J, MyD88, an adapter protein involved in interleukin-1 signaling, J Biol Chem, 273, 12203-12209, 1998.
164. Janssens S, Burns K, Tschopp J, Beyaert R, Regulation of interleukin-1-and lipopolysaccharideinduced NF-kappaB activation by alternative splicing of MyD88, Curr Biol, 12, 467-471, 2002.
165. Meshorer E, Soreq H, Virtues and woes of AChE alternative splicing in stress-related neuropathologies, Trends Neurosci, 29, 216-224, 2006.
166. Grisaru D, Sternfeld M, Eldor A, Glick D, Soreq H, Structural roles of acetylcholinesterase variants in biology and pathology, Eur J Biochem, 264, 672-686, 1999.
167. Brenner T, Hamra-Amitay Y, Evron T, Boneva N, Seidman S, Soreq H, The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis, FASEB J, 17, 214-222, 2003.
168. Shohami E, Kaufer D, Chen Y, Seidman S, Cohen O, Ginzberg D, Melamed-Book N, Yirmiya R, Soreq H, Antisense prevention of neuronal damages following head injury in mice, J Mol Med, 78, 228-236, 2000.
169. Nijholt I, Farchi N, Kye M, Sklan EH, Shoham S, Verbeure B, Owen D, Hochner B, Spiess J, Soreq H, Blank T, Stress-induced alternative splicing of acetylcholinesterase results in enhanced fear memory and long-term potentiation, Mol Psychiatry, 9, 174-183, 2004.
170. Vickers TA, Wyatt JR, Burckin T, Bennett CF, Freier SM, Fully modified 2′ MOE oligonucleotides redirect polyadenylation, Nucl Acids Res, 29, 1293-1299, 2001.
171. Gautheret D, Poirot O, Lopez F, Audic S, Claverie JM, Alternate polyadenylation in human mRNAs:a large-scale analysis by EST clustering, Genome Res, 8, 524-530, 1998.
172. Shaw G, Kamen R, A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation, Cell, 46, 659-667, 1986.
173. Sanford JR, Ellis J, Caceres JF, Multiple roles of arginine/serine-rich splicing factors in RNA processing, Biochem Soc Trans, 33, 443-446, 2005.
174. Cartegni L, Krainer AR, Correction of disease-associated exon skipping by synthetic exon-specific activators, Nat Struct Biol, 10, 120-125, 2003.
175. Muller D, Bonaiti-Pellie C, Abecassis J, Stoppa-Lyonnet D, Fricker JP, BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect, Fam Cancer, 3, 15-20, 2004.
176. Chabot B, LeBel C, Hutchison S, Nasim FH, Simard MJ, Heterogeneous nuclear ribonucleoprotein particle A/B proteins and the control of alternative splicing of the mammalian heterogeneous nuclear ribonucleoprotein particle A1 pre-mRNA, Prog Mol Subcell Biol, 31, 59-88, 2003.
177. Wilusz JE, Devanney SC, Caputi M, Chimeric peptide nucleic acid compounds modulate splicing of the bcl-x gene in vitro and in vivo, Nucl Acids Res, 33, 6547-6554, 2005.
178. Partridge M, Vincent A, Matthews P, Puma J, Stein D, Summerton J, A simple method for delivering morpholino antisense oligos into the cytoplasm of cells, Antisense Nucl Acid Drug Dev, 6, 169-175, 1996.
179. Skordis LA, Dunckley MG, Yue B, Eperon IC, Muntoni F, Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts, Proc Natl Acad Sci USA, 100, 4114-4119, 2003.
180. Villemaire J, Dion I, Elela SA, Chabot B, Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides, J Biol Chem, 278, 50031-50039, 2003.
181. Gendron D, Carriero S, Garneau D, Villemaire J, Klinck R, Elela SA, Damha MJ, Chabot B, Modulation of 5′ splice site selection using tailed oligonucleotides carrying splicing signals, BMC Biotechnol, 6, 5, 2006.
182. Mayer MG, Floeter-Winter LM, Pre-mRNA trans-splicing: from kinetoplastids to mammals, an easy language for life diversity, Mem Inst Oswaldo Cruz, 100, 501-513, 2005.
183. Puttaraju M, Jamison SF, Mansfield SG, Garcia-Blanco MA, Mitchell LG, Spliceosome-mediated RNA trans-splicing as a tool for gene therapy, Nat Biotechnol, 17, 246-252, 1999.
184. Schroder W, Rudlowski C, Biesterfeld S, Knobloch C, Hauptmann S, Rath W, Expression of CD44(v5-10) splicing variants in primary ovarian cancer and lymph node metastases, Anticancer Res, 19, 3901-3906, 1999.
185. Mansfield SG, Kole J, Puttaraju M, Yang CC, Garcia-Blanco MA, Cohn JA, Mitchell LG, Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing, Gene Ther, 7, 1885-1895, 2000.
186. Dallinger G, Puttaraju M, Mitchell LG, Yancey KB, Hintner H, Bauer JW, Collagen 17A1 gene correction using spliceosome mediated RNA trans-splicing (SMaRTtrade mark) technology, J Invest Dermatol, 115, 332, 2000.
187. Dallinger G, Puttaraju M, Mitchell LG, Yancey KB, Yee C, Klausegger A, Hintner H, Bauer JW, Development of spliceosome-mediated RNA trans-splicing (SMaRT) for the correction of inherited skin diseases, Exp Dermatol, 12, 37-46, 2003.
188. Rodriguez-Martin T, Garcia-Blanco MA, Mansfield SG, Grover AC, Hutton M, Yu Q, Zhou J, Anderton BH, Gallo JM, Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies, Proc Natl Acad Sci USA, 102, 15659-15664, 2005.
189. Tahara M, Pergolizzi RG, Kobayashi H, Krause A, Luettich K, Lesser ML, Crystal RG, Transsplicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency, Nat Med, 10, 835-841, 2004.
190. Chao H, Mansfield SG, Bartel RC, Hiriyanna S, Mitchell LG, Garcia-Blanco MA, Walsh CE, Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing, Nat Med, 9, 1015-1019, 2003.
191. Schumperli D, Pillai RS, The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein, Cell Mol Life Sci, 61, 2560-2570, 2004.
192. Sierakowska H, Sambade MJ, Agrawal S, Kole R, Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides, Proc Natl Acad Sci USA, 93, 12840-12844, 1996.
193. Gorman L, Suter D, Emerick V, Schumperli D, Kole R, Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs, Proc Natl Acad Sci USA, 95, 4929-4934, 1998.
194. Suter D, Tomasini R, Reber U, Gorman L, Kole R, Schumperli D, Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human beta-thalassemic mutations, Hum Mol Genet, 8, 2415-2423, 1999.
195. Gorman L, Mercatante DR, Kole R, Restoration of correct splicing of thalassemic beta-globin premRNA by modified U1 snRNAs, J Biol Chem, 275, 35914-35919, 2000.
196. Vacek MM, Ma H, Gemignani F, Lacerra G, Kafri T, Kole R, High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA, Blood, 101, 104-111, 2003.
197. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, Danos O, Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping, Science, 306, 1796-1799, 2004.
198. Denti MA, Rosa A, D’Antona G, Sthandier O, De Angelis FG, Nicoletti C, Allocca M, Pansarasa O, Parente V, Musaro A, Auricchio A, Bottinelli R, Bozzoni I, Chimeric adeno-associated virus/antisense U1 small nuclear RNA effectively rescues dystrophin synthesis and muscle function by local treatment of mdx mice, Hum Gene Ther, 17, 565-574, 2006.
199. Madocsai C, Lim SR, Geib T, Lam BJ, Hertel KJ, Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs, Mol Ther, 12, 1013-1022, 2005.
200. Liu S, Asparuhova M, Brondani V, Ziekau I, Klimkait T, Schumperli D, Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A, Nucl Acids Res, 32, 3752-3759, 2004.
201. Kashima T, Manley JL, A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy, Nat Genet, 34, 460-463, 2003.
202. Hofmann Y, Wirth B, hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1, Hum Mol Genet, 11, 2037-2049, 2002.
203. Massiello A, Salas A, Pinkerman RL, Roddy P, Roesser JR, Chalfant CE, Identification of two RNA cis-elements that function to regulate the 5′ splice site selection of Bcl-x pre-mRNA in response to ceramide, J Biol Chem, 279, 15799-15804, 2004.
204. Massiello A, Roesser JR, Chalfant CE, SAP155 Binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5′ splice site selection of Bcl-x pre-mRNA, FASEB J, 20, 1680-1682, 2006.
205. Gabut M, Mine M, Marsac C, Brivet M, Tazi J, Soret J, The SR protein SC35 is responsible for aberrant splicing of the E1alpha pyruvate dehydrogenase mRNA in a case of mental retardation with lactic acidosis, Mol Cell Biol, 25, 3286-3294, 2005.
206. Bolduc L, Labrecque B, Cordeau M, Blanchette M, Chabot B, Dimethyl sulfoxide affects the selection of splice sites, J Biol Chem, 276, 17597-17602, 2001.
207. Soret J, Bakkour N, Maire S, Durand S, Zekri L, Gabut M, Fic W, Divita G, Rivalle C, Dauzonne D, Nguyen CH, Jeanteur P, Tazi J, Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors, Proc Natl Acad Sci USA, 102, 8764-8769, 2005.
208. Tazi J, Bakkour N, Soret J, Zekri L, Hazra B, Laine W, Baldeyrou B, Lansiaux A, Bailly C, Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diospyrin derivatives, Mol Pharmacol, 67, 1186-1194, 2005.
209. Sazani P, Kang SH, Maier MA, Wei C, Dillman J, Summerton J, Manoharan M, Kole R, Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs, Nucl Acids Res, 29, 3965-3974, 2001.
210. Sazani P, Gemignani F, Kang SH, Maier MA, Manoharan M, Persmark M, Bortner D, Kole R, Systemically delivered antisense oligomers upregulate gene expression in mouse tissues, Nat Biotechnol, 20, 1228-1233, 2002.
211. Thierry AR, Abes S, Resina S, Travo A, Richard JP, Prevot P, Lebleu B, Comparison of basic peptidesand lipid-based strategies for the delivery of splice correcting oligonucleotides, Biochim Biophys Acta, 1758, 364-374, 2006.
212. Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL, Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides, Bioconjug Chem, 15, 290-299, 2004.
213. Moulton HM, Hase MC, Smith KM, Iversen PL, HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers, Antisense Nucl Acid Drug Dev, 13, 31-43, 2003.
214. Sazani P, Astriab-Fischer A, Kole R, Effects of base modifications on antisense properties of 2-Omethoxyethyl and PNA oligonucleotides, Antisense Nucl Acid Drug Dev, 13, 119-128, 2003.
215. Albertshofer K, Siwkowski AM, Wancewicz EV, Esau CC, Watanabe T, Nishihara KC, Kinberger GA, Malik L, Eldrup AB, Manoharan M, Geary RS, Monia BP, Swayze EE, Griffey RH, Bennett CF, Maier MA, Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid, J Med Chem, 48, 6741-6749, 2005.
216. Maier MA, Esau CC, Siwkowski AM, Wancewicz EV, Albertshofer K, Kinberger GA, Kadaba NS, Watanabe T, Manoharan M, Bennett CF, Griffey RH, Swayze EE, Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids, J Med Chem, 49, 2534-2542, 2006.
217. Roberts J, Palma E, Sazani P, Orum H, Cho M, Kole R, Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice, Mol Ther, 14, 471-475, 2006.